SCM
MYOV

Scopia Capital Management’s Myovant Sciences Ltd. MYOV Stock Holding History

Scopia Capital Management’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-817,747
Closed -$10.2M – 42
2016
Q4 		$10.2M Buy
+817,747
New +$9.48M 0.19% 35

Other funds holding MYOV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Scopia Capital Management's MYOV Position: Q1 2017 in Review

Scopia Capital Management sold out of Myovant Sciences Ltd. (MYOV) in Q1 2017, closing a stake of 817,747 shares — an estimated $10.2M sold.

Scopia Capital Management first reported a position in MYOV in Q4 2016 and held it in 1 quarter. The position peaked at $10.2M in Q4 2016. 48 funds tracked by Wall St. Rank hold MYOV as of Q1 2017.

  • Scopia Capital Management reported no remaining Myovant Sciences Ltd. position as of Q1 2017 after selling out during the quarter.
  • Scopia Capital Management sold 817,747 Myovant Sciences Ltd. shares in Q1 2017, an estimated $10.2M.
  • Scopia Capital Management first reported a position in Myovant Sciences Ltd. in Q4 2016 and held it in 1 quarter.
  • Scopia Capital Management's Myovant Sciences Ltd. position peaked at $10.2M in Q4 2016.
  • 48 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2017.

Based on Scopia Capital Management's 13F filing for Q1 2017, filed 15 May 2017.